Clarification regarding prequalification status of a Ugandan manufacturer
M
In accordance with the provisions set out in sec
Following corrective actions taken by Matrix Laboratories Ltd and the clarifications provided being
WHO is aware of the recent actions taken by the USA Food and Drug Administration (FDA) against the Ranbaxy, Paonta Sahib, India manufacturing site.
As changes in manufacturing sites and activities on sites may change, it is suggested that all users of the list of prequalified products and WHOPIRs verify with the manufacturers